tiprankstipranks
Trending News
More News >

Noxopharm Unveils Promising SOF-SKN Data at Rheumatology Conference

Story Highlights
Noxopharm Unveils Promising SOF-SKN Data at Rheumatology Conference

Don’t Miss TipRanks’ Half-Year Sale

An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.

Noxopharm Limited has presented new data on its novel drug candidate, SOF-SKN, at the Australian Rheumatology Association’s Annual Scientific Meeting. This marks the company’s first engagement with a specialist rheumatology audience. SOF-SKN, designed to treat autoimmune diseases like cutaneous lupus erythematosus, demonstrated significant reduction in inflammation in a rheumatology-relevant animal model. The upcoming HERACLES clinical trial will further evaluate its efficacy. This development underscores Noxopharm’s commitment to addressing the growing autoimmune disease market and enhancing its industry positioning.

More about Noxopharm Ltd.

Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company is pioneering technology to enhance a wide range of mRNA medicines and is targeting autoimmune diseases with its Sofra technology platform.

YTD Price Performance: -19.35%

Average Trading Volume: 83,002

Technical Sentiment Signal: Buy

Current Market Cap: A$21.92M

See more insights into NOX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1